Whitepaper writer – The future of monoclonal antibodies

Antibody engineering and therapeutics: The future of Monoclonal Antibodies

We want to explore the future of Monoclonal Antibodies (mAbs), both in the short term and longer term. The whitepaper could include (though is not limited to) the following:

- Short term future - which antibodies could soon be granted marketing approval? How many products are in late-stage clinical studies? Are there trends around them? What looks most promising?
- Looking further to the future where are antibody therapeutics going in the next 5-10 years?
- New technologies, applications and targets
- This is to be used as part of the marketing for the KNect365 Antibody Engineering and Therapeutics conference that can be found. Exploring the agenda will give you the best idea of the topics we cover and the areas wed like covered in this whitepaper.

We would like a whitepaper looking at these issues, opportunities and challenges written for an audience of biopharm industry professionals.

Words: 2000

Timelines:
- First draft for internal edits: 1 week after commission
- Edits returned to writer: 2 days after draft provided
- Final version deadline: 2 days after edited draft returned
About the recuiter
Member since Nov 11, 2022
Bashier
from Moscow, Russia

---

---

Looking for help? Checkout our video tutorial
How to search and apply for jobs

How to apply? Do you have more questions about the Job?
See frequently asked questions